The Food and Drug Administration (FDA) has designated Conexxence ® (denosumab-bnht) and Bomyntra ® (denosumab-bnht) as interchangeable biosimilars to the reference products Prolia ® (denosumab) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback